title: Oseltamivir treatment for children showing abnormal behavior during influenza virus infection.
abstract: We investigated the clinical courses of children with influenza infection, who showed abnormal behavior, who were treated with oseltamivir (Tamiflu).
  
  
  METHODS
  The subjects were 22 children, 2-15 (mean+/-SD, 6.6+/-3.2) years old, admitted to our hospital during the 2004-2005, 2005-2006, and 2006-2007 influenza seasons. Abnormal behavior appeared before treatment with oseltamivir in 13 children (pre-Tami group), and after administration of the medication in 9 (post-Tami group). All patients continued to receive oseltamivir for 3-5 days after admission.
  
  
  RESULTS
  Meaningless speech and movements without a specific purpose were the most frequent abnormal behavior (16 children), while illusions, delusions, and misidentifying awareness were the second most common (14 children). Sensations of marked fear and excitement were recognized in 6 children. One child rushed up and down the stairs unconsciously, raising concern that a serious accident might occur. All patients showed a favorable clinical course, without worsening of neurological symptoms or the development of encephalopathy, and outcomes were good. The clinical course, number of recurrences of abnormal behavior, and outcome were similar in the pre-Tami and post-Tami groups.
  
  
  CONCLUSIONS
  Our observations suggest that oseltamivir is not a prerequisite for the development of abnormal behavior and does not worsen the clinical manifestations of abnormal behaviors, although further investigations are needed to determine whether oseltamivir is necessary, or even useful, for patients with influenza virus encephalopathy.
authors.affiliation: Department of Pediatrics, Hirakata City Hospital, 2-14-1 Kinyahonmachi, Hirakata City, Osaka 573-1013, Japan. tanabemapa@pop01.odn.ne.jp
authors.forename: Takuya
authors.initials: T
authors.lastname: Tanabe
authors.forename: Keita
authors.initials: K
authors.lastname: Hara
authors.forename: Miwa
authors.initials: M
authors.lastname: Nakajima
authors.forename: Shuichi
authors.initials: S
authors.lastname: Shimakawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tamai
mesh_terms: D000293:Adolescent; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002653:Child Behavior Disorders / Q000150:complications*; D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D006801:Humans; D009980:Influenza A virus; D009981:Influenza B virus; D007251:Influenza, Human / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D001523:Mental Disorders / Q000150:complications*; D053139:Oseltamivir / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D053139:Oseltamivir